#HVO hVIVO plc – Omicron human challenge model update March 16, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that its Omicron human challenge agent has been successfully manufactured. Subject to the successful completion of the characterisation study and receipt of relevant regulatory approvals, this has expanded the Company’s unique portfolio to 11 human challenge models to test a…

#VELA Vela Technologies PLC investee co. #ENSI Ensilica PLC – EUR 5m Satellite Broadband Chip Contract Win February 17, 2023 – Posted in: Vela Technologies Plc (VELA)

EnSilica (AIM:ENSI), a leading mixed signal chip maker, is pleased to announce that it has been awarded a €5m contract to develop a new chip to address the next generation of mass market satellite broadband user terminals (the “Contract”). The Contract has been awarded in the framework of the European Space Agency’s (ESA) Advanced Research in Telecommunications Systems Core Competitiveness programme (“ARTES CC”), through the support of the UK Space Agency. The activities included in the Contract are…

#HVO hVIVO PLC – Long Term Incentive Plan / PDMR Notification February 6, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that on 6 February 2023, the Company implemented a Long Term Incentive Plan (“LTIP”) for Yamin ‘Mo’ Khan, the Company’s Chief Executive Officer. The LTIP has been designed to reward, incentivise and retain Mr Khan to deliver sustainable growth for shareholders.…

#VELA Vela Technologies PLC investee co. #KING Igraine PLC – Investment in Fixit Medical Ltd February 3, 2023 – Posted in: Vela Technologies Plc (VELA)

The Board of Igraine (AQSE:KING), an investing company focused on breakthrough innovative technologies and discoveries in the healthcare and life sciences sectors, announces a £100,000 cash investment into Fixit Medical Ltd (“Fixit”), the next generation drainage catheter fixation device. Further information on Fixit Fixit, a research and experimental development company focused on social sciences and humanities, is the sole owner, designer and developer of Cingo® (“Cingo”), the next drainage catheter fixation device. Cingo features best…

#ORPH Open Orphan PLC – Director dealings September 29, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has received notification that on 29 September 2022, Yamin ‘Mo’ Khan, Chief Executive Officer of the Company, purchased 510,204 ordinary shares of 0.1 pence each in the capital of the Company (“Shares”) at a price…

Alan Green covers #MNRG MetalNRG and #COIN Coinisilium on this week’s Stockbox Research Talks February 21, 2022 – Posted in: Blog, Coinsilium (COIN)

Alan Green covers #MNRG MetalNRG and #COIN Coinisilium on this week’s Stockbox Research Talks Listen to the podcast here

#ORPH Open Orphan Plc – $13.4m Influenza HCS contract win December 10, 2021 – Posted in: Blog, Open Orphan (ORPH)

(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a $13.4m contract with a US-based biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model. The study is expected to commence in H2 2022 and will be conducted at hVIVO’s state-of-the-art quarantine facilities in…

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate December 6, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office. The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its…

#POLB Poolbeg Pharma – Scientific Advisory Board Appointment November 25, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board . Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology…